



1300 I Street, NW • Washington, DC 20005-3315 • 202.408.4000 • Fax 202.408.4400 www.finnegan.com

July 23, 2004

ATTORNEY DOCKET NO. **2481.1734** CUSTOMER NO. 22,852

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

U.S. Patent Application No.: 09/762,893

Title: SUBSTITUTED 4-AMINO-2-ARYL-PYRIMIDINES,

THEIR PRODUCTION AND USE AND

PHARMACEUTICAL PREPARATIONS CONTAINING

SAME

Inventor(s): Ursula SCHINDLER et al.

Sir:

We enclose the following paper for filing in the United States Patent and Trademark Office in connection with the above patent application.

1. The extra claims fee is calculated as follows:

<u>AMENDMENT</u>							
	Number of Claims After Amendment		Highest # Previously Paid For	Extra Claims After Amendment			
Total Claims	27	-	26	1	x \$18		18.00
Ind. Claims	5	-	3	2	x \$86		172
☐ First Presentation of Multiple Dep. Claim(s) + \$290							
Subtotal						\$	190.00
Reduction by ½ if small entity						-	
TOTAL FEE						\$	190.00

2. A check for \$190.00 is enclosed.

The Commissioner is hereby authorized to charge any additional fees due and any other fees under 37 C.F.R. § 1.16 or § 1.17 during the pendency of this application to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Carlos M. Tellez

Reg. No. 48,638

Date: July 23, 2004



PATENT Customer Number 22,852 Attorney Docket No. **02481.1734**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1624

Examiner: Richard L. Raymond

In re Application of:

Ursula SCHINDLER et al.

Application No.: 09/762,893

Filed: February 13, 2001

For: SUBSTITUTED 4-AMINO-2-

ARYL-PYRIMIDINES, THEIR PRODUCTION AND USE AND

PHARMACEUTICAL

PREPARATIONS CONTAINING

SAME

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

RESPONSE AND AMENDMENT UNDER 37 C.F.R. § 1.111

In reply to the Office Action mailed April 27, 2004, and pursuant to 37 C.F.R. § 1.111, Applicants respectfully request the reexamination and reconsideration of this application in view of the following amendments and remarks.

Amendments to the specification begin on page 2 of this paper. Amendments to the claims are reflected on the listing of claims, which begins on page 3 of this paper.

Remarks begin on page 22 of this paper.

07/26/2004 EABUBAK1 00000041 09762893

01 FC:1201 02 FC:1202 172.00 OP 18.00 OP